69 related articles for article (PubMed ID: 38526790)
21. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
[TBL] [Abstract][Full Text] [Related]
22. Chemical genomics reveals histone deacetylases are required for core regulatory transcription.
Gryder BE; Wu L; Woldemichael GM; Pomella S; Quinn TR; Park PMC; Cleveland A; Stanton BZ; Song Y; Rota R; Wiest O; Yohe ME; Shern JF; Qi J; Khan J
Nat Commun; 2019 Jul; 10(1):3004. PubMed ID: 31285436
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.
Nguyen TH; Barr FG
Molecules; 2018 Oct; 23(11):. PubMed ID: 30373318
[TBL] [Abstract][Full Text] [Related]
24. Generation and validation of homozygous fluorescent knock-in cells using CRISPR-Cas9 genome editing.
Koch B; Nijmeijer B; Kueblbeck M; Cai Y; Walther N; Ellenberg J
Nat Protoc; 2018 Jun; 13(6):1465-1487. PubMed ID: 29844520
[TBL] [Abstract][Full Text] [Related]
25. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens.
Concordet JP; Haeussler M
Nucleic Acids Res; 2018 Jul; 46(W1):W242-W245. PubMed ID: 29762716
[TBL] [Abstract][Full Text] [Related]
26. Review of CRISPR/Cas9 sgRNA Design Tools.
Cui Y; Xu J; Cheng M; Liao X; Peng S
Interdiscip Sci; 2018 Jun; 10(2):455-465. PubMed ID: 29644494
[TBL] [Abstract][Full Text] [Related]
27. PAX3-FOXO1: Zooming in on an "undruggable" target.
Wachtel M; Schäfer BW
Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205
[TBL] [Abstract][Full Text] [Related]
28. Disruption of diphthamide synthesis genes and resulting toxin resistance as a robust technology for quantifying and optimizing CRISPR/Cas9-mediated gene editing.
Killian T; Dickopf S; Haas AK; Kirstenpfad C; Mayer K; Brinkmann U
Sci Rep; 2017 Nov; 7(1):15480. PubMed ID: 29133816
[TBL] [Abstract][Full Text] [Related]
29. Application of a novel HiBiT peptide tag for monitoring ATF4 protein expression in Neuro2a cells.
Oh-Hashi K; Furuta E; Fujimura K; Hirata Y
Biochem Biophys Rep; 2017 Dec; 12():40-45. PubMed ID: 28955790
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide.
Schwinn MK; Machleidt T; Zimmerman K; Eggers CT; Dixon AS; Hurst R; Hall MP; Encell LP; Binkowski BF; Wood KV
ACS Chem Biol; 2018 Feb; 13(2):467-474. PubMed ID: 28892606
[TBL] [Abstract][Full Text] [Related]
31. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements.
Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ
Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069
[TBL] [Abstract][Full Text] [Related]
32. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J
Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439
[TBL] [Abstract][Full Text] [Related]
33. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.
Joung J; Konermann S; Gootenberg JS; Abudayyeh OO; Platt RJ; Brigham MD; Sanjana NE; Zhang F
Nat Protoc; 2017 Apr; 12(4):828-863. PubMed ID: 28333914
[TBL] [Abstract][Full Text] [Related]
34. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells.
Kleinstiver BP; Tsai SQ; Prew MS; Nguyen NT; Welch MM; Lopez JM; McCaw ZR; Aryee MJ; Joung JK
Nat Biotechnol; 2016 Aug; 34(8):869-74. PubMed ID: 27347757
[TBL] [Abstract][Full Text] [Related]
36. NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells.
Dixon AS; Schwinn MK; Hall MP; Zimmerman K; Otto P; Lubben TH; Butler BL; Binkowski BF; Machleidt T; Kirkland TA; Wood MG; Eggers CT; Encell LP; Wood KV
ACS Chem Biol; 2016 Feb; 11(2):400-8. PubMed ID: 26569370
[TBL] [Abstract][Full Text] [Related]
37. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells.
Chu VT; Weber T; Wefers B; Wurst W; Sander S; Rajewsky K; Kühn R
Nat Biotechnol; 2015 May; 33(5):543-8. PubMed ID: 25803306
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Shern JF; Chen L; Chmielecki J; Wei JS; Patidar R; Rosenberg M; Ambrogio L; Auclair D; Wang J; Song YK; Tolman C; Hurd L; Liao H; Zhang S; Bogen D; Brohl AS; Sindiri S; Catchpoole D; Badgett T; Getz G; Mora J; Anderson JR; Skapek SX; Barr FG; Meyerson M; Hawkins DS; Khan J
Cancer Discov; 2014 Feb; 4(2):216-31. PubMed ID: 24436047
[TBL] [Abstract][Full Text] [Related]
39. Genome engineering using the CRISPR-Cas9 system.
Ran FA; Hsu PD; Wright J; Agarwala V; Scott DA; Zhang F
Nat Protoc; 2013 Nov; 8(11):2281-2308. PubMed ID: 24157548
[TBL] [Abstract][Full Text] [Related]
40. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Hinson AR; Jones R; Crose LE; Belyea BC; Barr FG; Linardic CM
Front Oncol; 2013; 3():183. PubMed ID: 23882450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
